ID
35115
Descrizione
Study ID: 107495 Clinical Study ID: 107495 Study Title: A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H5N1) influenza vaccine (split virus formulation) adjuvanted with AS03, administered according to different vaccination schedules. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00430521 https://clinicaltrials.gov/ct2/show/NCT00430521 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Pandemic influenza vaccine (GSK1119711A)-formulation 1, Pandemic influenza vaccine (GSK1119711A)-formulation 2 Trade Name: N/A Study Indication: Influenza There are 4 workbooks (WB): WB 1: Protocol 107495, (H5N1-012), Groups: VT/VT/6Mo, VT/IN/6Mo WB 2: Protocol 107495, (H5N1-012), Groups: VT/VT/12Mo, VT/IN/12Mo WB 3: Protocol 107495 (H5N1-012) GROUPS: 2VT/VT/6MO, 2VT/IN/6MO WB 4: Protocol 107495 (H5N1-012) Groups: 2VT/VT/12Mo, 2VT/IN/12Mo Every Workbook has the following visits: Visit Day 0 (Screening, Dose 1), Visit Day 21, Visit Month 6, Visit Month 12 and Visit Month 18. After Month 6 (+30 days, if applicable) and Month 12 (+30 days, if applicable) there is a Core Analysis section, followed by a final study conclusion after Month 18. Workbook 1 schedules a vaccination at screening and Month 6 each, Workbook 2 at Screening and Month 12. 30 days after the first vaccination there is an additional telephone contact. After the second vaccination additional visits/contacts are necessary in both workbooks: a visit at Month 6/12 + 7 and 21 days and a telephone contact on Month 6/12 + 30 days. Workbook 3 schedules a vaccination at screening, Day 21 and Month 6 and Workbook 4 at screening, Day 21 and Month 12. After the second vaccination there is an additional visit on Day 42 and a telephone contact on day 51. After the third vaccination there are additional visits/contacts: visits at Month 6/12 + 7 and 21 days and a telephone contact at Month 6/12 + 30 days. After Month 6 (+30 days, if applicable) and Month 12 (+30 days, if applicable) there is a Core Analysis section. This document contains the demography, informed consent and randomisation/ treatment allocation form. It has to be filled in for screening for all workbooks (WB1-4).
collegamento
https://clinicaltrials.gov/ct2/show/NCT00430521
Keywords
versioni (2)
- 18/02/19 18/02/19 -
- 20/09/21 20/09/21 -
Titolare del copyright
GlaxoSmithKline
Caricato su
18 febbraio 2019
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Evaluation of reactogenicity and immunogenicity of pandemic monovalent (H5N1) influenza vaccine in adults, NCT00430521
Demography, informed consent, randomisation/ treatment allocation
Descrizione
Informed consent
Alias
- UMLS CUI-1
- C0021430
Descrizione
Randomisation/ Treatment Allocation
Alias
- UMLS CUI-1
- C1522541
Descrizione
Demography
Alias
- UMLS CUI-1
- C0011298
Descrizione
Center number
Tipo di dati
text
Alias
- UMLS CUI [1,1]
- C1301943
- UMLS CUI [1,2]
- C0600091
Descrizione
day month year
Tipo di dati
date
Alias
- UMLS CUI [1]
- C0421451
Descrizione
Sex
Tipo di dati
text
Alias
- UMLS CUI [1]
- C0079399
Descrizione
Ethnicity
Tipo di dati
integer
Alias
- UMLS CUI [1]
- C0015031
Descrizione
Race
Alias
- UMLS CUI-1
- C0034510
Descrizione
A person having origins in any of the black racial groups of Africa
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C0085756
- UMLS CUI [2]
- C0027567
Descrizione
A person having origins in any of the original peoples of North and South America (including Central America) and who maintains tribal affiliation or community attachment
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C1515945
Descrizione
A person having origins in Central Asia and Indian Subcontinent (India, Pakistan, Bangladesh and Sri Lanka)
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C0238696
- UMLS CUI [2]
- C1519427
Descrizione
A person having origins in China, Korea
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C4540996
Descrizione
A person having origins in Japan
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C1556094
Descrizione
A person having origins in Malaysia, the Philippines, Indonesia, Thailand, Vietnam, Laos, Burma or Cambodia
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C0238697
Descrizione
A person having origins in any of the original peoples of Hawaii, Guam, Samoa or other Pacific Islands, Australia (Aborigines), Papua New Guinea, New Zealand, Marshalls and other island groups west and south of Japan
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C1513907
Descrizione
A person having origins in any of the original peoples of Middle East or North Africa
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C0238604
- UMLS CUI [2]
- C2698217
Descrizione
A person having origins in any of the original peoples of Europe
Tipo di dati
boolean
Alias
- UMLS CUI [1]
- C0043157
Descrizione
Other racial group
Tipo di dati
boolean
Alias
- UMLS CUI [1,1]
- C0034510
- UMLS CUI [1,2]
- C0205394
Descrizione
Other racial group, specification
Tipo di dati
text
Alias
- UMLS CUI [1,1]
- C0034510
- UMLS CUI [1,2]
- C0205394
Similar models
Demography, informed consent, randomisation/ treatment allocation
C0011008 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
C0027567 (UMLS CUI [2])
C1519427 (UMLS CUI [2])
C2698217 (UMLS CUI [2])
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])